Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowContinuing expansion of its direct-to-patient pharmacy, Eli Lilly and Co. on Wednesday announced it is partnering with Walmart to allow consumers to pick up single-dose vials of weight-loss blockbuster drug Zepbound—ordered through LillyDirect.com—at the retailer’s pharmacies nationwide, starting by mid-November.
The Indianapolis-based drug giant’s LillyDirect pharmacy offers direct-to-consumer pricing, or self-pay pricing, that offers a 50% or greater discount compared with the list price of other GLP-1 medicines for obesity, Lilly said. The move comes as more employers consider whether to cover GLP-1’s for obesity in their health benefit plans, and as patients seeking to lose weight look for ways to pay for the costly medicines.
Walmart, the nation’s largest retail chain by revenue, has nearly 4,600 pharmacies across the country, according to Lilly.
Single-dose vials of Zepbound, with the active ingredient tirzepatide, will be available in all approved strengths, with the lowest dose of 2.5 mg for $349 per month with self-pay to be ordered online at LillyDirect and picked up at a Walmart pharmacy. Other doses (5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) are $499 a month.
Some patients save money on Zepbound by ordering larger vials and splitting their doses, which allow them to inject the medicine weekly with a syringe, instead of a preloaded pen. However, Lilly says that practice is not recommended for safety reasons.
“Managing a chronic disease like obesity can be a significant and ongoing burden—physically, emotionally, and financially,” Jennifer Mazur, Lilly senior vice president and general manager of LillyDirect, said in written remarks. “This collaboration with Walmart is designed to reduce that burden by streamlining access to prescribed treatment.”
Lilly launched its LillyDirect pharmacy in January 2024 with the service now offering medicines—typically delivered at home—in areas including dermatology, diabetes, obesity, migraine and sleep apnea.
The move comes as Lilly increasingly is reaching out to patients directly about cost and access to its highly popular obesity treatment, Zepbound.
In June, Lilly hosted its first “Ask Me Anything” session on the popular online forum Reddit, featuring a question-and-answer session with a Lilly executive about insurance coverage and access to Zepbound.
Lilly reported that Zepbound’s revenue was $3.38 billion in the United States in the second quarter, an increase of 172% from the same period of 2024. Lilly reports third-quarter earnings Thursday.
Morgan Stanley estimates that by 2030, the U.S. market for obesity drugs could reach $80 billion, more than half of the $150 billion global estimate.
Please enable JavaScript to view this content.
Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.